Skip to search formSkip to main contentSkip to account menu

ABT 538

Known as: ABT-538, ABT538 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ritonavir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Identifying and Characterizing HIV Protease Inhibitors.
HIV protease catalyzes the hydrolysis of specific peptide bonds of viral polyproteins, thus processing these polyproteins into… 
1996
1996
Use of ritonavir (ABT-538) to enhance the pharmacokinetics of cytochrome p450 farmacosmetabolizados in a method of treatment of AIDS.
Uso de ritonavir o una sal farmaceuticamente aceptable del mismo para mejorar la farmacocinetica de un farmaco (o una sal… 
1996
1996
The use of ritonavir to improve the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating AIDS (abt-538)
There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV… 
1996
1996
Use of ritonavir (ABT-538) to improve the pharmaco-kinetics of drugs that are metabolized cytochrome p450 in a method of treatment of AIDS.
A combination of ritonavir or a pharmaceutically acceptable salt thereof and a drug which is metabolized by cytochrome P450… 
1996
1996
Use of ritonavir (ABT-538) to improve the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treatment of AIDS.
It DESCRIBED a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase. 
1996
1996
How 'bout that ritonavir?
The protease inhibitor ABT-538 (ritonavir) is available through a compassionate use program. Qualifications include a CD4 cell… 
1995
1995
ABT-538 increases CD4 counts.
ABT-538, a new protease inhibitor, appears to increase CD4 counts and viral load in HIV-infected persons. In a four-week placebo… 
1995
1995
Protease inhibitor update.
New clinical trial developments surrounding anti-HIV compounds, known as protease inhibitors, are discussed for the following… 
1995
1995
Protease developers skirmish over possible pitfalls.
Protease inhibitors were the dominating topic at the Second National Conference on Human Retroviruses and Related Infections… 
1994
1994
SAFETY, PHARMACOKINETICS AND VIROLOGICAL/IMMUNOLOGICAL EFFICACY OF ABT-538, A HIV-PROTEASE INHIBITOR. A RANDOMISED, PLACEBO-CONTROLLED PHASE I/II STUDY